secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2026-05-11T20:10:43+00:00
Accession:  0001493152-26-022227
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q1 revenue $44.2M, net loss $27.6M; VEVYE market share reaches 14%
-------------------------------------------------------------------------

- Revenue of $44.2M, down 8% YoY, including ~$8M non-recurring gross-to-net adjustment related to new VEVYE commercial coverage.
- Net loss of $27.6M ($0.74 diluted EPS) vs. loss of $17.8M ($0.50) in Q1 2025; Adjusted EBITDA -$12.7M.
- VEVYE delivered record quarterly prescriptions: NRx +25% QoQ, TRx +11% QoQ; surpassed XIIDRA on monthly TRx with ~14% market share.
- IHEEZO unit demand +18% YoY to 45,509 units (82% from retina); TRIESENCE unit demand +136% YoY for 6th consecutive growth quarter.
- Q2 2026 revenue guidance $71M-$81M; full-year 2026 revenue reaffirmed $350M-$365M, Adjusted EBITDA $80M-$100M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/0001493152-26-022227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315226022227/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer